HBM Healthcare Investments Increases NAV and Expects CHF 272 Million Profit

HBM Healthcare Investments AG has completed its 2025/2026 financial year, witnessing a 17.2% rise in net asset value (NAV) in Swiss francs. Meanwhile, its share price surged by 28.5%. This growth is attributed to a favorable biotechnology sector and several key transactions involving both private and publicly listed companies within its portfolio. Notable transactions include acquisitions of companies like Merus and Y-mAbs Therapeutics by larger pharmaceutical enterprises.

Despite these gains, the appreciation of the Swiss franc against HBM's primary investment currencies negatively impacted the annual results. The preliminary figures, which are unaudited, foreshadow an expected annual profit of CHF 272 million for 2025/2026. The detailed and final results are set to be released on 13 May 2026.